| abstract |
The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor βγ complex (LL-2Κβ) over IL-2 receptor αβγ complex (LL-2Rα). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed. |